Jeffrey Arcara - 28 Feb 2024 Form 4 Insider Report for Corvus Pharmaceuticals, Inc. (CRVS)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRVS	Stock Option (Right to Buy)	Award	$0	+400,000		$0.000000	400,000	28 Feb 2024	Common Stock	400,000	$2.30	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from February 2, 2024, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.